Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Rev. bras. cir. cardiovasc ; 34(3): 271-278, Jun. 2019. tab, graf
Article in English | LILACS | ID: biblio-1013463

ABSTRACT

Abstract Objective: The goal of the present study was to compare the myocardial protection obtained with histidine-tryptophan-ketoglutarate (HTK) cardioplegic solution (Custodiol®) and with intermittent hypothermic blood solution. Methods: Two homogenous groups of 25 children with acyanotic congenital heart disease who underwent total correction with mean aortic clamping time of 60 minutes were evaluated in this randomized study. Troponin and creatine kinase-MB curves, vasoactive-inotropic score, and left ventricular function were obtained by echocardiogram in each group. The values were correlated and presented through graphs and tables after adequate statistical treatment. Results: It was observed that values of all the studied variables varied over time, but there was no difference between the groups. Conclusion: We conclude that in patients with acyanotic congenital cardiopathies submitted to total surgical correction, mean aortic clamping time around one hour, and cardiopulmonary bypass with moderate hypothermia, the HTK crystalloid cardioplegic solution offers the same myocardial protection as the cold-blood hyperkalemic cardioplegic solution analyzed, according to the variables considered in our study model.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Cardioplegic Solutions/therapeutic use , Heart Defects, Congenital/surgery , Potassium Chloride/therapeutic use , Procaine/therapeutic use , Reference Values , Time Factors , Troponin/analysis , Echocardiography , Double-Blind Method , Prospective Studies , Reproducibility of Results , Analysis of Variance , Ventricular Function, Left , Treatment Outcome , Statistics, Nonparametric , Protective Agents/therapeutic use , Creatine Kinase, MB Form/analysis , Operative Time , Glucose/therapeutic use , Heart Defects, Congenital/physiopathology , Mannitol/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL